Retinal Disorder Treatment Global Market Report 2023 – By Type (Macular Degeneration, Diabetic Retinopathy, Other Types), By Dosage Form (Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Market Size, Trends, And Global Forecast 2023-2032

Vitreoretinal surgery devices are specialized medical instruments that have typically incorporated a peristaltic pump, a venturi pump, or a combination of both to manage fluids. It is used for the removal of core vitrectomy, membrane cutting, and hyaloid and vitreous bases. These vitreoretinal surgical instruments feature improved flow control and less retinal traction. The main product types of vitreoretinal surgery devices are photocoagulation lasers, illumination devices, vitrectomy machines, vitrectomy probes, vitreoretinal packs, and others. Photocoagulation lasers refer to medical devices that are used to shrink or destroy abnormal structures in the retina. The various surgery includes anterior vitreoretinal surgery, and posterior vitreoretinal surgery. These are used in various applications such as diabetic vitreous hemorrhage, retinal detachment, macular hole, and others, used by various end-users such as hospitals, specialty clinics, ambulatory surgery centers, and others. The global vitreoretinal surgery devices market is segmented - 1) By Product: Photocoagulation Lasers, Illumination Devices, Vitrectomy Machines, Vitrectomy Probes, Vitreoretinal Packs, Other Products 2) By Surgery: Anterior Vitreoretinal Surgery, Posterior Vitreoretinal Surgery 3) By Application: Diabetic Vitreous Hemorrhage, Retinal Detachment, Macular Hole, Other Applications 4) By End-Users: Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Other End-Users The global vitreoretinal surgery devices market size is expected to grow from $1.7 billion in 2022 to $1.99 billion in 2023 at a compound annual growth rate (CAGR) of 6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global vitreoretinal surgery devices market size is expected to reach $2.43 billion in 2027 at a CAGR of 5.2%. Growing incidences of eye disorders are expected to propel the growth of the vitreoretinal surgery device market going forward. Eye disorders refer to non-neoplastic or neoplastic disorders that affect the eye. Vitreoretinal surgery devices are used to treat eye diseases such as macular degeneration, cataracts, diabetes-related retinopathy, glaucoma, and retinal detachment. For instance, in December 2022, according to the Centers for Disease Control and Prevention, a US-based federal agency, in the United States, 12 million persons aged 40 and older would have vision impairment, of which 1 million are blind, 3 million have it after having their vision corrected, and 8 million have it because of uncorrected refractive error. Therefore, the increasing incidence of eye disorders drives the vitreoretinal surgery device market. Major players in the vitreoretinal surgery devices market are Alcon Inc., Bausch & Lomb Inc., OCULUS Optikgerate Gmbh, MedOne Surgical Inc., Carl Zeiss Meditec AG, Peregrine Surgical Group Pvt. Ltd., D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Paragon Care Group Pvt. Ltd., Topcon Corporation, Geuder AG, IRIDEX Corporation, Ellex Medical Lasers, Erbe Elektromedizin, Design For Vision Inc., and BVI Medical Inc. Product innovation is a key trend gaining popularity in the vitreoretinal surgery device market. Companies operating in the vitreoretinal surgery device market are working on new product innovations to sustain their position in the market. For instance, in June 2020, BVI, a US-based medical device manufacturer, launched a new vitreoretinal surgery device called CryoTreq, the world’s first single-use handheld cryo-surgery device expanding its vitreoretinal portfolio. This device revolutionizes the treatment of retinal tears and detachments. This stand-alone cryosurgery tool operates without external connections to machinery, gas tanks, or power and is service- and maintenance-free. In October 2022, DORC Dutch Ophthalmic Research Center (International) BV, a Netherlands-based medical device manufacturer, acquired Peregrine Surgical LLC and WEFIS GmbH for an undisclosed amount. With this acquisition, DORC expands its manufacturing capabilities, supporting the strategic goal of reaching the #2 position in the US retina market and would drive the development of laser and illumination technologies. Peregrine Surgical LLC is a US-based medical device manufacturer of devices that are used in vitreoretinal surgeries. WEFIS GmbH is a Germany-based company that manufactures vitreoretinal surgical instruments. North America was the largest region in the vitreoretinal surgery devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global vitreoretinal surgery devices market report during the forecast period. The regions covered in the global vitreoretinal surgery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vitreoretinal surgery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The vitreoretinal surgery devices market consists of sales squeezers, luer locks, forceps, and surgical instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The vitreoretinal surgery devices market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal surgery devices market statistics, including vitreoretinal surgery devices industry global market size, regional shares, competitors with a vitreoretinal surgery devices market share, detailed vitreoretinal surgery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the vitreoretinal surgery devices industry. This vitreoretinal surgery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hyperpigmentation disorder treatment refers to the various methods used to reduce the appearance of dark spots or patches on the skin that occur due to excess melanin production. Topical creams containing ingredients such as hydroquinone, vitamin C, and azelaic acid can be used to lighten the skin. The treatment types involved in the hyperpigmentation disorder treatment market include cosmeceuticals, laser therapy, chemical peels, microdermabrasion, phototherapy and other treatments. Cosmeceuticals are cosmetics with active ingredients that may be therapeutic for the skin. They are used to treat various diseases including melasma, post-inflammatory hyperpigmentation, solar lentigines and other indications by various end-users such as hospitals, esthetic clinics and dermatology centers and other end-users. The global hyperpigmentation disorder treatment market is segmented - 1) By Treatment Type: Cosmeceuticals, Laser Therapy, Chemical Peels, Microdermabrasion, Phototherapy, Other Treatments 2) By Disease Indication: Melasma, Post-Inflammatory Hyperpigmentation, Solar Lentigines, Other Disease Indications 3) By End-Users: Hospitals, Esthetic Clinics And Dermatology Centers, Other End-Users The global hyperpigmentation disorder treatment market size is expected to grow from $4.94 billion in 2022 to $5.30 billion in 2023 at a compound annual growth rate (CAGR) of 7.19%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hyperpigmentation disorder treatment market size is expected to reach $7.09 billion in 2027 at a CAGR of 7.58%. Rise in prevalence of pigmentation disorders is expected to drive the growth of the hyperpigmentation disorders treatment market. Pigmentation disorders encompass a range of conditions that impact the coloration of the skin, hair, and eye iris. These disorders arise due to issues with melanin, the pigment produced by melanocytes that plays a role in determining skin, hair, and eye color. Treatment options for hyperpigmentation disorders vary depending on the underlying cause and severity of the condition. Mild cases can often be managed with over-the-counter topical creams containing ingredients like azelaic acid, cysteamine cream, vitamin C, and hydroquinone, which possess skin-lightening properties. For instance, in March 2023, according to the Centers for disease control (CDC) report, a US-based federal agency of health, the incidence of Candida auris (C. auris) cases increased from 476 in 2019 to 1,471 in 2021 in the US and the number of cases being screened tripled between 2020 and 2021, reaching 4,041 in total. Additionally, in December 2022, according to the National Psoriasis Foundation, a US-based nonprofit organization serving people with psoriasis and psoriatic arthritis, Psoriasis affects 125 million people globally, accounting for 2 to 3 percent of the overall population, where it affects approximately 1.5 percent of African Americans compared to 3.6 percent of Caucasians. Therefore, rise in prevalence of pigmentation disorders is expected to proper the growth of the hyperpigmentation disorders treatment market. Major players in the hyperpigmentation disorder treatment market are Vivier Pharma, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, EpiPharm AG, Laboratories Pierre Fabre, SkinCeuticals, Galderma S.A., Allergan PLC., Bayer AG, Lumenis Be Ltd., Aerolase Corporation, Candela Corporation, Cynosure, Galderma S.A. and PCA Skin. Product innovation is a key trend gaining popularity in the hyperpigmentation disorders treatment market. Major companies operating in the hyperpigmentation disorders treatment market are focused on developing innovative products to strengthen their position and gain competitive advantage. For instance, in October 2021, Uniza Healthcare, an India-based pharmaceutical company launched a novel treatment product named Vitellus. It is a lotion that contains a unique combination of EUK-134, Greyverse, and Melitane GL 200, which helps in the growth of melanin and works on skin pigmentation, hair follicle pigmentation, and acts as a super antioxidant. In December 2021, DermBiont, Inc., a US-based biotechnology company acquired Chroma Dermatology for an undisclosed amount. With this acquisition, DermBiont has broadened its drug pipeline to encompass the management of skin hyperpigmentation conditions, such as melasma and solar lentigos, alongside seborrheic keratosis, atopic dermatitis, seborrheic dermatitis, and acne. Chroma Dermatology is a US-based clinical-stage biotechnology company. North America was the largest region in the hyperpigmentation disorders treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global hyperpigmentation disorder treatment market report during the forecast period. The regions covered in the global hyperpigmentation disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyperpigmentation disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hyperpigmentation disorder treatment market consists of revenues earned by entities by providing hyperpigmentation disorder treatment services such as microdermabrasion and tropical treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperpigmentation disorder treatment market also includes sales of serums, creams, gels or lotions formulated for the treatment of hyperpigmentation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hyperpigmentation disorder treatment market research report is one of a series of new reports from The Business Research Company that provides hyperpigmentation disorder treatment optical components market statistics, including hyperpigmentation disorder treatment optical components industry global market size, regional shares, competitors with a hyperpigmentation disorder treatment optical components market share, detailed hyperpigmentation disorder treatment optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hyperpigmentation disorder treatment optical components industry. This hyperpigmentation disorder treatment optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy. The global anemia and other blood disorder drugs market is segmented – 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV) The global anemia and other blood disorder drugs market size will grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global anemia and other blood disorder drugs is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the anemia and other blood disorder drugs market. Major players in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC., Akebia Therapeutics, Bayer AG, Pfizer Inc., Regenbiopharma, Hoffmann-La Roche Ltd., Merck Sharp &Dohme Corp., Novartis AG and Janssen Pharmaceutical. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the anemia and other blood disorder drugs market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc. to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotech company operating in anemia and other blood disorder drugs. North America was the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anemia and other blood disorder drugs market during the forecast period. The regions covered in the global anemia and other blood disorder drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacy, retail pharmacy, and online pharmacy. The global neurodegenerative disorder therapeutics market is segmented - 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy The global neurodegenerative disorder therapeutics market size grew from $15.86 billion in 2022 to $17.14 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the neurodegenerative disorder therapeutics is expected to grow from $23.65 billion in 2027 at a CAGR of 8.4%. Increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering from Alzheimer’s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the neurodegenerative disorder therapeutics market. Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd., ACADIA Pharmaceuticals Inc., Lundeck A/S, Boehringer Ingeiheim International GmbH, Merck Serono, Orion Pharma Ltd., Mitsubishi Tanabe Pharma America, Allergan, GlaxoSmith Kline PLC., AbbVie, Eli lilly, Celgene, Neuro- Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation, AstraZeneca, Alector, Yumanity Therapeutics, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical and Eisai. High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently, very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials. For instance, 12 of the 42 (28 percent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate of 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics hurts the market, hindering its growth of the neurodegenerative disorder therapeutics market. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market to increase their capabilities for research and development activities to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in July 2022, NRG Therapeutics, a UK-based drug discovery company focussed on therapeutic approaches, partnered with Domainex, a UK-based drug discovery service, to develop neurodegenerative disease treatment. For the treatment of Parkinson's disease, motor neurone disease (MND), and other incapacitating chronic neurodegenerative conditions, the firms would work together to develop novel small molecule disease-modifying medications. In January 2020, Biogen Inc., an American biotechnology company, paid $75 million for a novel clinical-stage asset, PF-05251749, as well as the applications from Pfizer.The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS-penetrant regulator that has the potential to treat behavioural and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc. is a multinational pharmaceutical company based in the USA. North America was the largest region in the global neurodegenerative disorder therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Diagnostic and monitoring ophthalmic devices and equipment market are used for the diagnosis and monitoring of diseases related to the retina and cornea by measuring affix lenses and refractive errors. These devices also help identify the intraocular lenses (IOLs) and analyze the visual field. The main product types in the diagnostic and monitoring ophthalmic devices and equipment market are optical coherence tomographers, ophthalmic ultrasound imaging systems, fundus cameras, ophthalmoscopes, keratometers, specular microscopes., tonometers, slit lamps, retinoscopes, and others (dioptometers, optotype projector, perimeters, and biometers, pachymeters, autorefractors/phoropters, corneal topographers, wavefront aberrometer, wavefront aberrometer). Fundus cameras are used for diagnosing and monitoring and are used in imaging of a rear eye. These are used in various applications such as retinal evaluation, glaucoma detection, and monitoring, surgical evaluation, general examination, intraoperative devices, and refraction equipment. Diagnostic and monitoring ophthalmic devices market are used in hospitals, clinics, diagnostic laboratories, and research centers. The global diagnostic and monitoring ophthalmic devices and equipment market is segmented - 1) By Product Type: Optical coherence tomographers, Ophthalmic ultrasound imaging systems, Fundus cameras, Ophthalmoscopes, Keratometers, Specular microscopes., Tonometers, Slit Lamps, Retinoscopes, Others (Dioptometers, Optotype projector, Perimeters, and Biometers, Pachymeters, Autorefractors/phoropters, Corneal topographers, Wavefront abberometers, Wavefront abberometers) 2) By End User: Hospitals, Clinics, Diagnostic Laboratories, Research Centers 3) By Application: Retinal evaluation, Glaucoma detection and monitoring, Surgical evaluation, General examine, Intraoperative devices, Refraction equipment The global diagnostic and monitoring ophthalmic devices and equipment market size will grow from $2.5 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diagnostic and monitoring ophthalmic devices and equipment is expected to grow from $3.6 billion in 2027 at a CAGR of 7.3%. The increasing prevalence of eye diseases is expected to drive the demand for diagnostic and monitoring equipment market in the ophthalmic devices industry. The rise in surgeries associated with eye disorders like cataracts, diabetic retinopathy, and glaucoma has increased the demand for diagnostic and monitoring ophthalmic devices and equipment market. According to a study, 4 out of 10 people have been found to have cataract disease in their early stages of life. The absolute number of cataract blind in 2020 would be 8.25 million, due to a substantial increase in the population above 50 years in India. Major players in the diagnostic and monitoring ophthalmic devices and equipment market are Carl Zeiss Meditec, Alcon, Bausch + Lomb, Haag-Streit, Topcon Corporation, Nidek Co. Ltd., Abbott Medical Optics, Johnson and Johnson Vision Care, Essilor International S.A, and Ziemer Ophthalmic Systems AG. Lack of awareness about eye diseases mostly in developing and underdeveloped nations is expected to hinder the growth of the diagnostic and monitoring ophthalmic devices and equipment market. A lack of awareness of eye disorders results in fewer patients going for a routine eye check-up or diagnosis of the disorder, impacting the demand for diagnostic and monitoring ophthalmic equipment. According to a study conducted by the vision impact institute, 42% of drivers in India have vision-related problems leading to 59% of road accidents. According to WHO, 550 million people in the country need vision correction and to achieve this, companies should increase awareness & provide vision care to people living in rural and semi-urban areas. Advanced eye care medical devices equipped with artificial intelligence (AI) and machine learning (ML) are the new trends in the ophthalmic diagnostic and monitoring equipment market. AI and ML-equipped medical devices can not only quickly interpret the eyes of the patient with better accuracy but also recommend a suitable treatment for the patient. Deepmind, a subsidiary of Alphabet Inc. has developed an AI-based system that is capable of analyzing 3D retinal OCT scans for detecting severe diseases like glaucoma, retinopathy, macular degeneration, and 50 different types of eye diseases at their early stage. The increased regulatory compliance norms by the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have impacted the market making the approval/regulation process for diagnostic and monitoring ophthalmic devices strenuous. Complex and tedious premarket and postmarket submissions by FDA may increase the product release time and incur heavy costs on device development. The MHRA considers a medical device to be any equipment used for the diagnosis or treatment of disease, or for monitoring patients and recommends Yellow card reporting for ophthalmic devices and products as well. All the adverse events and the causes for any untoward incidents must be reported in the yellow card, allowing the equipment to be monitored thoroughly for enhanced patient safety. In July 2020, Topcon, a company manufacturing optical equipment based in Japan acquired Elektron Eye Technology for an undisclosed amount. This acquisition includes the products of the Henson line of perimetry such as Henson 9000 and 7000 that perform suprathreshold glaucoma screening and the product manufacturing will remain in the UK. Elektron Eye Technology is a company operating in the diagnostic and monitoring of ophthalmic devices based in the UK. North America was the largest region in the global diagnostic and monitoring ophthalmic devices and equipment market in 2022. Asia-Pacific was the second-largest market in diagnostic and monitoring ophthalmic devices and equipment market report. The regions covered in the diagnostic and monitoring ophthalmic devices and equipment industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diagnostic and monitoring ophthalmic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The Diagnostic and monitoring ophthalmic devices and equipment market consist of sales of ultrasound imaging systems ophthalmoscopes, corneal topographers, specular microscopes, slit lamps, fundus cameras, anomaloscope, haploscope, ophthalmic lens gauge, stereopsis measuring Instrument, retinoscopes, stereoscope, and others that are used for diagnosis and monitoring of ophthalmic diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diagnostic and monitoring ophthalmic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides diagnostic and monitoring ophthalmic devices and equipment market statistics, including diagnostic and monitoring ophthalmic devices and equipment industry global market size, regional shares, competitors with a diagnostic and monitoring ophthalmic devices and equipment market share, detailed diagnostic and monitoring ophthalmic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic and monitoring ophthalmic devices and equipment industry. This diagnostic and monitoring ophthalmic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuroprosthetics is the study of neuroprostheses and brain-machine interfaces. Neuroprosthetic devices substitute the cognitive or sensory functions that have been impaired due to nervous system disorders. They encompass various artificial devices or systems that can enhance the output or input of a neural system. The major purpose of neuroprosthetics is to allow brain-injured patients to participate in day-to-day life and improve their quality of life. The main types of neuroprosthetics are motor neuroprosthetics, auditory neuroprosthetics/ cochlear implants, visual neuroprosthetics/ retinal implants, and cognitive neuroprosthetics. As an orthosis, motor neuroprosthesis (MN) includes electrical stimulation of brain areas to promote the activities and involvement of persons who have had a stroke in their natural environment. The various techniques used are spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and transcranial magnetic stimulation which are applied in various disorders such as motor neuron disorders, physiological disorders, and cognitive disorders. The global neuroprosthetics market is segmented - 1) By Type: Motor Neuroprosthetics, Auditory Neuroprosthetics/ Cochlear implants, Visual Neuroprosthetics/ Retinal implants, Cognitive Neuroprosthetics 2) By Technique: Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation 3) By Application: Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders The global neuroprosthetics market size grew from $8.09 billion in 2022 to $9.24 billion in 2023 at a compound annual growth rate (CAGR) of 14.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the neuroprosthetics market is expected to grow to $16.03 billion in 2027 at a CAGR of 14.7%. The rising patient population suffering from neurological disorders and nerve injuries is expected to propel the growth of the neuroprosthetics market. Neurological disorders are referred to as disorders that affect the brain and the nerves present in the human body and the spinal cord. Nerve injuries are the damages caused to nerves due to pressure, cuts, or stretching during an accident or any unpredicted event. Neuroprosthetics help patients with such disorders and injuries to restore their lost motor and sensory functions. For instance, according to the world Health Oganization (WHO), a Switzerland-based health agency of the united nations, in 2022, 50 million people globally were suffering from epilepsy, nearly 80% of them were living in low and middle-income countries. Therefore, the growing patient population suffering from neurological disorders and nerve injuries is driving the growth of the neuroprosthetics market. Major players in the neuroprosthetics market are Medtronic plc, Cochlear Ltd., Abbott Laboratories, Boston Scientific, LivaNova PLC., Second Sight Medical Products Inc., MED-EL, Retina Implant AG, Sonova, Neuropace, NDI Medical LLC, Demant AS, Oticon, St. Jude Medical Inc. and Biomet Inc. Technological advancements are shaping the neuroprosthetics market. Technological advancement is defined as a discovery of knowledge that advances technology to provide an enhanced product to the customers. For instance, in July 2021, the University of California San Francisco Parnassus Campus (UCSF), a US-based academic medical center, developed Speech Neuroprosthesis. The new achievement was developed by researchers of UCSF, which enabled paralysis patients to directly translate the signals from their brain to the vocal tract, which appear as text on the screen. The technology used is Brain-Computer Interface Restoration of Arm and Voice which uses human vocabulary with advanced computer algorithms that are used to recognize brain activity. In February 2021, Flow Neuroscience, a Sweden-based developer of a brain stimulation device, acquired Halo Neuroscience, for an undisclosed amount. With this acquisition, Flow Neuroscience aims at providing more personalized solutions related to brain disorders. Halo Neuroscience is a US-based developer of brain stimulators that develops muscle memory faster and develops and designs neuroprosthetics. North America was the largest region in the neuroprosthetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroprosthetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuroprosthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The neuroprosthetics market includes revenues earned by entities by peripheral nerve, brain-computer interface, electro stimulation, neurostimulation, cochlear implant, stimulation, femoral nerve and carbon nanotube. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The neuroprosthetics market research report is one of a series of new reports from The Business Research Company that provides neuroprosthetics market statistics, including neuroprosthetics industry global market size, regional shares, competitors with a neuroprosthetics market share, detailed neuroprosthetics market segments, market trends and opportunities, and any further data you may need to thrive in the neuroprosthetics industry. This neuroprosthetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinal biologics refers to bioengineered macromolecules that are implanted inside the eyes to heal chronic retinal diseases. They are highly precise inflammatory mediator-targeting compounds used to treat inflammatory, corneal, and retinal medical conditions. The main types of retinal biologics are vascular endothelial growth factor (VEGF)-A antagonist and tumor necrosis factor (TNF)-A inhibitor. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor, and an essential growth factor for vascular endothelial cells. They are administered for various indications, such as macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are available in hospitals, pharmacies, specialty clinics, online pharmacies, and others. The global retinal biologics market is segmented - 1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor 2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications 3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels The global retinal biologics market size is expected to grow from $19.83 billion in 2022 to $22.48 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of retinal biologics market is expected to reach $35.46 billion in 2027 at a CAGR of 12.1%. The increasing prevalence of diabetic eye disease is expected to propel the growth of the retinal biologics market going forward. Diabetic eye disease is a complication of diabetes that affects the eyes by causing vision loss and blindness in people with diabetes. Retinal biologics hold the potential for more precise and effective treatment options, allowing for earlier intervention and improved outcomes in preventing vision loss associated with diabetic eye disease. For instance, in February 2020, the International Diabetes Federation (IDF), a Belgium-based diabetes organization, estimated that about 191 million people living with diabetes are estimated to develop diabetic retinopathy (an eye condition that can cause vision loss and blindness in people who have diabetes) by 2030. Further, as per estimates, there are 56.3 million people who would develop deteriorating, vision-threatening diabetic retinopathy. Therefore, the increasing prevalence of diabetic eye disease is driving the growth of the retinal biologics market. Major players in the retinal biologics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co Inc, AbbVie Inc., Bayer AG, Janssen Biotech, Novartis AG, Fresenius SE, AstraZeneca plc, Boehringer Ingelheim International GmbH., Amgen Inc, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd., Sanofi Genzyme, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum, Ocular Therapeutix, Alimera Sciences, Adverum Biotechnologies Inc., MeiraGTx Limited, Oxurion NV, Graybug Vision Inc., Kodiak Sciences Inc., Clearside Biomedical Inc., UCBCares, Allergan plc, Genentech Inc., Iveric bio Inc., Neurotech Pharmaceuticals Inc., and Opthea Limited. Product innovation is a key trend gaining popularity in the retinal biologics market. Major companies operating in the retinal biologics market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced that the U.S. Food and Drug Administration had accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). Acceptance was based on two Phase III trials that showed early and persistent visual improvement with Vabysmo, achieving the primary endpoint of non-inferiority to aflibercept. This product is the first bispecific antibody approved for the eye to treat neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Further studies showed an absence of blood vessel leakage in the retina in Vabysmo patients compared to aflibercept patients. In January 2023, Coherus BioSciences Inc., a US-based biosimilar therapeutics company, acquired exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States for an undisclosed sum. This ophthalmology-acquired product will enable Coherus to extensively target anti-VEGF medications, significantly extending its market opportunity to support mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm that offers anti-VEGF medications. North America was the largest region in the retinal biologics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The retinal biologics market research report is one of a series of new reports from The Business Research Company that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Retinal biologics refers to bioengineered macromolecules that are implanted inside the eyes to heal chronic retinal diseases. They are highly precise inflammatory mediator-targeting compounds used to treat inflammatory, corneal, and retinal medical conditions. The main types of retinal biologics are vascular endothelial growth factor (VEGF)-A antagonist and tumor necrosis factor (TNF)-A inhibitor. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor, and an essential growth factor for vascular endothelial cells. They are administered for various indications, such as macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are available in hospitals, pharmacies, specialty clinics, online pharmacies, and others. The global retinal biologics market is segmented - 1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor 2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications 3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels The global retinal biologics market size is expected to grow from $19.83 billion in 2022 to $22.48 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of retinal biologics market is expected to reach $35.46 billion in 2027 at a CAGR of 12.1%. The increasing prevalence of diabetic eye disease is expected to propel the growth of the retinal biologics market going forward. Diabetic eye disease is a complication of diabetes that affects the eyes by causing vision loss and blindness in people with diabetes. Retinal biologics hold the potential for more precise and effective treatment options, allowing for earlier intervention and improved outcomes in preventing vision loss associated with diabetic eye disease. For instance, in February 2020, the International Diabetes Federation (IDF), a Belgium-based diabetes organization, estimated that about 191 million people living with diabetes are estimated to develop diabetic retinopathy (an eye condition that can cause vision loss and blindness in people who have diabetes) by 2030. Further, as per estimates, there are 56.3 million people who would develop deteriorating, vision-threatening diabetic retinopathy. Therefore, the increasing prevalence of diabetic eye disease is driving the growth of the retinal biologics market. Major players in the retinal biologics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co Inc, AbbVie Inc., Bayer AG, Janssen Biotech, Novartis AG, Fresenius SE, AstraZeneca plc, Boehringer Ingelheim International GmbH., Amgen Inc, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd., Sanofi Genzyme, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum, Ocular Therapeutix, Alimera Sciences, Adverum Biotechnologies Inc., MeiraGTx Limited, Oxurion NV, Graybug Vision Inc., Kodiak Sciences Inc., Clearside Biomedical Inc., UCBCares, Allergan plc, Genentech Inc., Iveric bio Inc., Neurotech Pharmaceuticals Inc., and Opthea Limited. Product innovation is a key trend gaining popularity in the retinal biologics market. Major companies operating in the retinal biologics market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced that the U.S. Food and Drug Administration had accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). Acceptance was based on two Phase III trials that showed early and persistent visual improvement with Vabysmo, achieving the primary endpoint of non-inferiority to aflibercept. This product is the first bispecific antibody approved for the eye to treat neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Further studies showed an absence of blood vessel leakage in the retina in Vabysmo patients compared to aflibercept patients. In January 2023, Coherus BioSciences Inc., a US-based biosimilar therapeutics company, acquired exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States for an undisclosed sum. This ophthalmology-acquired product will enable Coherus to extensively target anti-VEGF medications, significantly extending its market opportunity to support mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm that offers anti-VEGF medications. North America was the largest region in the retinal biologics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The retinal biologics market research report is one of a series of new reports from The Business Research Company that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.